MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
EXPAREL$575,130K (4.77%↑ Y/Y)ZILRETTA$116,633K (-1.23%↓ Y/Y)Iovera$24,178K (5.98%↑ Y/Y)Bupivacaine LiposomeInjectable Suspension$6,913K (-5.59%↓ Y/Y)Product$722,854K Royalty$3,557K Total revenues$726,411K (3.63%↑ Y/Y)Income (loss) fromoperations$19,191K (126.16%↑ Y/Y)Total operatingexpenses$707,220K (-8.67%↓ Y/Y)Income (loss) beforeincome taxes$16,874K (126.74%↑ Y/Y)Total other (expense)income, net-$2,317K (-122.57%↓ Y/Y)Interest income$22,732K (15.46%↑ Y/Y)Selling, general andadministrative$368,759K (25.39%↑ Y/Y)Cost of goods sold$149,749K (-12.13%↓ Y/Y)Research and development$117,312K (43.81%↑ Y/Y)Amortization of acquiredintangible assets$57,288K (0.00%↑ Y/Y)Contingent considerationgains,...$14,112K (83.23%↑ Y/Y)Net income (loss)$7,034K (107.07%↑ Y/Y)Income tax expense$9,840K (-73.01%↓ Y/Y)Interest expense$17,446K (5.29%↑ Y/Y)Other, net-$6,620K (-1674.80%↓ Y/Y)(loss) gain on earlyextinguishment of debt-$983K (-113.08%↓ Y/Y)
Income Statement
source: myfinsight.com

Pacira BioSciences, Inc. (PCRX)

Pacira BioSciences, Inc. (PCRX)